Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 May 31;13(5):893-896.
doi: 10.21037/tau-23-674. Epub 2024 May 8.

Radiohybrid prostate-specific membrane antigen ligand: new frontier in prostate cancer imaging and therapy

Kamran Masood  1 , Joseph R Steiner  2 , Emmanuel S Antonarakis  3 , Zuzan Cayci  1
Affiliations
Editorial

Radiohybrid prostate-specific membrane antigen ligand: new frontier in prostate cancer imaging and therapy

Kamran Masood et al. Transl Androl Urol. .
No abstract available

Keywords: LIGHTHOUSE trial; Radiohybrid prostate-specific membrane antigen ligands (rh PSMA ligands); prostate carcinoma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-23-674/coif). E.S.A. reports grants from Astellas, AstraZeneca, Bayer, Bristol-Myers, Squibb, Celgene, Clovis, MacroGenics, Merck, Novartis, Orion, and Seagen; consulting fees from Aadi Bioscience, Amgen, AstraZeneca, Bayer, Blue Earth Diagnostics, Curium, EcoR1, Hookipa Pharma, Janssen, Lilly, Menarini Silicon Biosystems, Merck, Pfizer, Sanofi, Tango Therapeutics, Tempus, and z-Alpha; and obtained patented AR-V7 biomarker technology licensed to Qiagen. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
18F-rhPSMA-7.3 PET scan fused images in a patient with prostate carcinoma post radical prostatectomy and pelvic lymph node dissection. (A) Axial fused image demonstrating focal radiotracer uptake (arrow) in the prostatectomy bed. (B) Sagittal fused image in the same patient again demonstrating focal uptake (arrow) in the prostatectomy bed. PT, prostate tumor; rhPSMA, radiohybrid prostate-specific membrane antigen; PET, positron emission tomography.
See this image and copyright information in PMC

Comment on

References

    1. Wurzer A, Di Carlo D, Schmidt A, et al. Radiohybrid Ligands: A Novel Tracer Concept Exemplified by 18F- or 68Ga-Labeled rhPSMA Inhibitors. J Nucl Med 2020;61:735-42. 10.2967/jnumed.119.234922 - DOI - PMC - PubMed
    1. Langbein T, Wang H, Rauscher I, et al. Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology. J Nucl Med 2022;63:1334-42. 10.2967/jnumed.121.263440 - DOI - PubMed
    1. Surasi DS, Eiber M, Maurer T, et al. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE). Eur Urol 2023;84:361-70. 10.1016/j.eururo.2023.06.018 - DOI - PubMed
    1. Tolvanen T, Kalliokoski K, Malaspina S, et al. Safety, Biodistribution, and Radiation Dosimetry of 18F-rhPSMA-7.3 in Healthy Adult Volunteers. J Nucl Med 2021;62:679-84. 10.2967/jnumed.120.252114 - DOI - PMC - PubMed
    1. Zacho HD, Nielsen JB, Haberkorn U, et al. 68 Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. Clin Physiol Funct Imaging 2017. doi:.10.1111/cpf.12480 - DOI - PubMed

LinkOut - more resources